Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

Company Focus & Drug Development - Cytokinetics is focused on muscle biology, particularly related to specialty heart disease, developing potential new medicines for cardiovascular conditions [3] - The company is developing a next-generation medicine that could potentially enter the same space as Bristol Myers' drug, with potential FDA approval later this year [5] - Cytokinetics has spent billions of dollars advancing a portfolio of potential medicines [8] - The company aims to expand the number of physicians comfortable prescribing these medicines for the benefit of more patients [6] - Cytokinetics is advancing a next-generation opportunity from the same research platform, hoping it will be available to patients later this year and dramatically expand the number of patients who could benefit [9] Financial Performance & Strategy - Fuego stock is up 60% in just the past three months [2] - Cytokinetics has raised primarily nonequity dilutive capital to reach its current position [12] - The company aims to set a high watermark for how it accesses and deploys capital, with a capital structure friendly to shareholders [12] - Cytokinetics' financial engineering has gone hand in hand with research and development over the past 25+ years [12] Partnerships & Commercialization - Bristol Myers is commercializing a medicine discovered in Cytokinetics' laboratories, which was the subject of a company they acquired [4] - Cytokinetics formed a company funded by venture capitalists that spun out of its laboratories and developed a medicine acquired by BMS [9]